AK119, A CD73 TARGETING ANTIBODY WITH DUAL MECHANISM OF ACTION

被引：1
|
作者：
Huang, Zhaoliang [1 ]
Pang, Xinghua [2 ]
Zhong, Tingting [2 ]
Jin, Chunshan [2 ]
Chen, Na [2 ]
He, Xinrong [2 ]
Xia, Dennis [2 ]
Jin, Xiaoping [3 ]
Wang, Zhongmin [2 ]
Xia, Xu [2 ]
Li, Baiyong [2 ]
机构：
[1] Akeso Bliopharma Inc, Zhongshan, Peoples R China
[2] Akeso Biopharma Inc, Zhongshan, Peoples R China
[3] Akeso Biopharma Inc, Potomac, MD USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷
关键词：
D O I：
10.1136/jitc-2021-SITC2021.750
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
750
引用
收藏
页码：A783 / A784
页数：2
相关论文
共 50 条
  • [1] AK119, A HUMANIZED ANTI-CD73 MONOCLONAL ANTIBODY, AS IMMUNOTHERAPY FOR COVID-19
    Zhong, Tingting
    Huang, Zhaoliang
    Pang, Xinghua
    Chen, Na
    Kwek, Konyew
    Wynne, Chris
    Konpa, Adam
    Jin, Xiaoping
    Xia, Yu
    Wang, Maxwell Zhongmin
    Li, Baiyong
    Xia, Yu
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A292 - A293
  • [2] Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action
    Geoghegan, James C.
    Diedrich, Gundo
    Lu, Xiaojun
    Rosenthal, Kim
    Sachsenmeier, Kris F.
    Wu, Herren
    Dall'Acqua, William F.
    Damschroder, Melissa M.
    MABS, 2016, 8 (03) : 454 - 467
  • [3] A therapeutic antibody that inhibits CD73 activity by dual mechanisms
    Barnhart, Bryan C.
    Sega, Emanuela
    Yamniuk, Aaron
    Hatcher, Sandra
    Lei, Ming
    Ghermazien, Haben
    Lewin, Anne
    Wang, Xi-Tao
    Huang, Haichun
    Zhang, Pingping
    Korman, Alan
    CANCER RESEARCH, 2016, 76
  • [4] Targeting CD73 to improves tumor immunotherapy
    Zhang, Bin
    Jin, Dachuan
    Fan, Jie
    Wang, Long
    Thompson, Linda
    Liu, Aijie
    Daniel, Ben
    Shin, Tahiro
    Curiel, Tyler
    JOURNAL OF IMMUNOLOGY, 2010, 184
  • [5] Targeting CD73 to augment cancer immunotherapy
    Roh, Meejeon
    Wainwright, Derek A.
    Wu, Jennifer D.
    Wan, Yong
    Zhang, Bin
    CURRENT OPINION IN PHARMACOLOGY, 2020, 53 : 66 - 76
  • [6] A phase I study of AK119, an anti-CD73 monoclonal antibody, in combination with AK104, an anti-PD-1/CTLA-4 bispecific antibody, in patients with advanced or metastatic solid tumors.
    Markman, Ben
    Hsieh, Amy Hsin-Chieh
    Coward, Jermaine
    Carlino, Matteo S.
    Frentzas, Sophia
    Jin, Xiaoping
    Li, Baiyong
    Wang, Zhongmin Maxwell
    Kwek, Kon Yew
    Xia, Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] The therapeutic potential of targeting CD73 and CD73-derived adenosine in melanoma
    Soleimani, Anvar
    Farshchi, Helale Kaboli
    Mirzavi, Farshad
    Zamani, Parvin
    Ghaderi, Amir
    Amini, Yousef
    Khorrami, Shadi
    Mashayekhi, Kazem
    Jaafari, Mahmoud Reza
    BIOCHIMIE, 2020, 176 : 21 - 30
  • [8] Immune-modulating vaccines targeting CD73
    Luo, Yuting
    Shi, Tao
    Wang, Hanbing
    Liu, Baorui
    Wei, Jia
    CANCER RESEARCH, 2024, 84 (06)
  • [9] Targeting two distinct epitopes on human CD73 with a bispecific antibody improves anticancer activity
    Gammelgaard, Odd L.
    Terp, Mikkel G.
    Renn, Christian
    Labrijn, Aran F.
    Hamaker, Oliver
    Nielsen, Aaraby Y.
    Vever, Henriette
    Hansen, Soren Wk
    Gjerstorff, Morten F.
    Muller, Christa E.
    Parren, Paul Whi
    Ditzel, Henrik J.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (09)
  • [10] AK131, an anti-PD1/CD73 bispecific antibody for cancer immune therapy.
    Huang, Zhaoliang
    Pang, Xinghua
    Zhong, Tingting
    Jin, Chunshan
    Chen, Na
    Xia, Dennis
    Zhang, Peng
    Wang, Max
    Xia, Michelle
    Li, Baiyong
    CANCER RESEARCH, 2022, 82 (12)
12345